Menu

Multiple Sclerosis

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

, ,

New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume loss were more likely to experience disease progression. Patients who remained free of disease had consistently lower rates of brain volume loss compared to […]

Real-world evidence showed superiority of Novartis’ Gilenya® to reduce MS relapse rates compared to interferons or glatiramer acetate

, ,

Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual’s level of disability Recovering from a relapse can take weeks […]